Variant-Matched Vaccines

Task II uses an immunobridging marker measured against the currently circulating variant. The Task II model scales controlled risk by a relative transmissibility factor. Placebo risk in the new variant setting is not identifiable from immunobridging data alone. Task II evaluates a variant-matched investigational vaccine against a new single circulating strain using immune measurements against that strain.